Hospital
Ascension Ne Wisconsin, INC
Ascension Ne Wisconsin, INC was paid $19.89M by Medicaid between Jan 2018 and Dec 2024, across 342 billing codes. Its largest line is 99283, emergency room visit (moderate) — 10% of everything it billed.
33Billing provider infoASCENSION NE WISCONSIN, INC
APPLETON, WI 54915
APPLETON, WI 54915
33aNPI1407803638assigned 05/31/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$19.89M
24GClaims1,050,789
24DCodes billed342
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Wisconsin
Rank by total paid#8 of 60
Median peer was paid$2.90M
This provider vs. median6.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official MCCULLOUGH, MICHAEL controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 150,460 | $3.21M | |
| 2019 | 215,873 | $3.93M | |
| 2020 | 145,976 | $2.65M | |
| 2021 | 153,525 | $2.55M | |
| 2022 | 153,395 | $2.72M | |
| 2023 | 146,548 | $2.77M | |
| 2024incomplete | 85,012 | $2.06M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 10% | 31,170 | 26,458 | $2.00M |
| 96361 | Intravenous infusion, hydration; each additional hour | 9.6% | 17,872 | 11,787 | $1.91M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 6.8% | 26,290 | 21,660 | $1.36M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.5% | 24,440 | 18,890 | $1.09M |
| 80053 | Comprehensive metabolic panel | 5.0% | 54,031 | 39,657 | $993K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.5% | 7,007 | 6,114 | $505K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.3% | 7,342 | 5,815 | $462K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 2.3% | 6,139 | 4,487 | $450K |
| G0378 | Hospital observation service, per hour | 2.1% | 8,062 | 5,202 | $422K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.0% | 6,409 | 4,344 | $394K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1.7% | 3,749 | 3,152 | $337K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.7% | 5,670 | 4,607 | $330K |
330 more codes
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 1.6% | 9,399 | $317K |
| 84443 | Thyroid stimulating hormone (TSH) | 1.5% | 20,107 | $294K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.5% | 20,774 | $293K |
| 99213 | Doctor's office visit, returning patient (routine) | 1.5% | 6,102 | $291K |
| H2012 | Behavioral health day treatment, per hour | 1.4% | 10,222 | $277K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 1.4% | 9,136 | $277K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.4% | 4,257 | $272K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 1.0% | 4,420 | $206K |
| G0306 | Complete cbc, automated (hgb, hct, rbc, wbc, without platelet count) and automated wbc differential count | <1% | 22,817 | $195K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 4,584 | $194K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 1,518 | $189K |
| 80061 | Lipid panel | <1% | 14,919 | $178K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 30,904 | $166K |
| 80306 | <1% | 10,349 | $162K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,986 | $157K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 6,477 | $151K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,750 | $148K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 2,350 | $138K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 3,000 | $135K |
| 87631 | <1% | 1,001 | $134K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 3,251 | $129K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 2,102 | $125K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,868 | $125K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 12,901 | $125K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 3,087 | $118K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 4,651 | $116K |
| 81001 | <1% | 25,114 | $114K | |
| 84702 | <1% | 4,775 | $113K | |
| 99001 | <1% | 5,356 | $107K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 1,803 | $103K |
| H0005 | Alcohol and/or drug services; group counseling by a clinician | <1% | 4,712 | $95K |
| 87653 | <1% | 2,540 | $90K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 4,681 | $89K |
| 84484 | <1% | 10,455 | $87K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 10,103 | $85K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,018 | $80K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 1,990 | $79K |
| 96415 | <1% | 1,126 | $74K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 6,543 | $72K |
| 87634 | <1% | 1,366 | $69K | |
| 82728 | <1% | 5,202 | $65K | |
| 85610 | <1% | 14,419 | $65K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,847 | $64K |
| 83690 | <1% | 12,180 | $64K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 3,432 | $63K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 4,927 | $62K |
| 81025 | <1% | 5,535 | $61K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 740 | $61K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,441 | $60K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 480 | $57K |
| 84703 | <1% | 8,013 | $57K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,187 | $52K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 277 | $52K |
| 0240U | <1% | 1,608 | $50K | |
| 87081 | <1% | 1,768 | $49K | |
| 82947 | <1% | 8,023 | $48K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,668 | $47K |
| G0379 | Direct admission of patient for hospital observation care | <1% | 1,314 | $47K |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 1,492 | $46K |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 2,308 | $45K |
| 82607 | <1% | 3,498 | $44K | |
| 82565 | <1% | 3,808 | $43K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 3,360 | $43K |
| 87210 | <1% | 5,414 | $42K | |
| 85027 | <1% | 8,617 | $42K | |
| 84439 | <1% | 3,630 | $42K | |
| 80076 | <1% | 3,677 | $42K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 4,039 | $42K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,020 | $41K |
| G0307 | Complete (cbc), automated (hgb, hct, rbc, wbc; without platelet count) | <1% | 6,947 | $41K |
| 83735 | <1% | 8,595 | $39K | |
| 86803 | <1% | 3,671 | $39K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 600 | $38K |
| 86780 | <1% | 4,413 | $38K | |
| 83880 | <1% | 2,133 | $37K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 841 | $37K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 1,019 | $36K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 505 | $34K |
| 93017 | <1% | 826 | $34K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,740 | $34K |
| J9271 | Injection, pembrolizumab, 1 mg | <1% | 30 | $33K |
| 83655 | <1% | 2,256 | $32K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 212 | $31K |
| 86762 | <1% | 2,319 | $31K | |
| 87340 | <1% | 3,963 | $31K | |
| H0022 | Alcohol and/or drug intervention service (planned facilitation) | <1% | 1,462 | $31K |
| 84145 | <1% | 1,980 | $30K | |
| 85379 | <1% | 3,837 | $30K | |
| 97597 | <1% | 945 | $29K | |
| 12001 | <1% | 373 | $28K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 418 | $28K |
| 82950 | <1% | 2,645 | $28K | |
| 87506 | <1% | 165 | $28K | |
| 84153 | <1% | 1,389 | $27K | |
| 87077 | <1% | 2,620 | $27K | |
| 86140 | <1% | 5,840 | $27K | |
| 82962 | <1% | 3,318 | $26K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 395 | $25K |
| 87186 | <1% | 3,726 | $25K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 636 | $24K |
| 86850 | <1% | 4,462 | $24K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 18,909 | $24K |
| 74018 | <1% | 2,467 | $24K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 2,304 | $23K |
| 83605 | <1% | 2,847 | $22K | |
| 82247 | <1% | 957 | $22K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,992 | $22K |
| 93971 | <1% | 571 | $21K | |
| 93226 | <1% | 939 | $20K | |
| 80143 | <1% | 1,873 | $20K | |
| 80179 | <1% | 1,844 | $19K | |
| 76642 | <1% | 480 | $18K | |
| 83540 | <1% | 3,492 | $18K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 7,763 | $17K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 466 | $17K |
| 87070 | <1% | 1,618 | $17K | |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 56 | $16K |
| 87040 | <1% | 1,486 | $16K | |
| 84481 | <1% | 1,106 | $15K | |
| 82077 | <1% | 1,773 | $15K | |
| 83550 | <1% | 2,381 | $15K | |
| 86787 | <1% | 2,416 | $14K | |
| 86481 | <1% | 169 | $14K | |
| 82043 | <1% | 2,682 | $14K | |
| 86038 | <1% | 1,340 | $13K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 19,590 | $13K |
| 85730 | <1% | 3,537 | $13K | |
| 12011 | <1% | 109 | $12K | |
| 83970 | <1% | 392 | $12K | |
| 82550 | <1% | 2,214 | $12K | |
| 76770 | <1% | 220 | $12K | |
| 82746 | <1% | 1,179 | $12K | |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 129 | $12K |
| 85018 | <1% | 2,988 | $11K | |
| 84460 | <1% | 2,521 | $11K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 799 | $11K |
| 84450 | <1% | 2,210 | $11K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 38 | $11K |
| 85007 | <1% | 3,459 | $10K | |
| 80164 | <1% | 383 | $10K | |
| 86900 | <1% | 3,767 | $10K | |
| 76830 | Ultrasound, transvaginal | <1% | 246 | $10K |
| 97162 | <1% | 406 | $9K | |
| 71250 | <1% | 403 | $9K | |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 631 | $9K |
| 30140 | <1% | 17 | $9K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 3,415 | $8K |
| 86901 | <1% | 3,769 | $8K | |
| 59025 | Fetal non-stress test | <1% | 115 | $8K |
| 86618 | <1% | 491 | $8K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 277 | $8K |
| 96367 | <1% | 103 | $8K | |
| 85652 | <1% | 3,184 | $8K | |
| 83718 | <1% | 906 | $7K | |
| 82465 | <1% | 1,177 | $7K | |
| 84146 | <1% | 402 | $7K | |
| 80050 | General health panel | <1% | 164 | $7K |
| 82570 | <1% | 1,454 | $7K | |
| 93458 | <1% | 17 | $7K | |
| 87088 | <1% | 1,082 | $7K | |
| 84466 | <1% | 786 | $7K | |
| 95806 | <1% | 100 | $6K | |
| 99460 | <1% | 74 | $6K | |
| 80178 | <1% | 277 | $6K | |
| 71045 | Radiologic examination, chest; single view | <1% | 12,864 | $6K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 14 | $6K |
| 87205 | <1% | 1,525 | $6K | |
| 82803 | <1% | 384 | $5K | |
| 84132 | <1% | 866 | $5K | |
| 82150 | <1% | 661 | $5K | |
| 84156 | <1% | 1,327 | $5K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 15,107 | $5K |
| 90715 | <1% | 745 | $5K | |
| 80074 | <1% | 145 | $4K | |
| 84144 | <1% | 148 | $4K | |
| 86706 | <1% | 455 | $4K | |
| 70486 | <1% | 142 | $4K | |
| 86480 | <1% | 65 | $4K | |
| 84550 | <1% | 841 | $4K | |
| 70496 | <1% | 60 | $4K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 104 | $4K |
| 81015 | <1% | 140 | $4K | |
| 94060 | <1% | 181 | $4K | |
| 85014 | <1% | 756 | $3K | |
| 82784 | <1% | 239 | $3K | |
| 36591 | <1% | 388 | $3K | |
| 81003 | <1% | 936 | $3K | |
| 72141 | <1% | 62 | $3K | |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | <1% | 18 | $3K |
| 82040 | <1% | 304 | $3K | |
| 70498 | <1% | 60 | $3K | |
| 83001 | <1% | 211 | $3K | |
| 76536 | <1% | 58 | $3K | |
| 87147 | <1% | 608 | $3K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 54,846 | $2K |
| 88307 | <1% | 201 | $2K | |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 73 | $2K |
| 73630 | <1% | 1,225 | $2K | |
| 97116 | <1% | 270 | $2K | |
| 94729 | <1% | 132 | $2K | |
| 93225 | <1% | 131 | $2K | |
| 93975 | <1% | 52 | $2K | |
| 99462 | <1% | 74 | $2K | |
| 82951 | <1% | 69 | $2K | |
| 73030 | <1% | 714 | $2K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 76 | $2K |
| 84403 | <1% | 70 | $2K | |
| 87272 | <1% | 54 | $2K | |
| 84100 | <1% | 524 | $1K | |
| 73110 | <1% | 509 | $1K | |
| 86200 | <1% | 140 | $1K | |
| 88304 | <1% | 657 | $1K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 73 | $1K |
| 94770 | <1% | 125 | $1K | |
| 70491 | <1% | 31 | $1K | |
| 86364 | <1% | 133 | $1K | |
| 97166 | <1% | 40 | $1K | |
| 77066 | Tomosynthesis, mammo | <1% | 51 | $1K |
| 97035 | <1% | 110 | $1K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 34 | $1K |
| 72040 | <1% | 18 | $1K | |
| 86258 | <1% | 111 | $995.15 | |
| 73130 | <1% | 665 | $949.59 | |
| 96417 | <1% | 94 | $945.35 | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 26 | $942.76 |
| 73610 | <1% | 1,329 | $923.00 | |
| 76942 | <1% | 141 | $834.89 | |
| 74019 | <1% | 82 | $834.43 | |
| 73564 | <1% | 645 | $753.67 | |
| 72100 | <1% | 214 | $740.54 | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 76 | $733.12 |
| 73221 | <1% | 14 | $723.02 | |
| 73502 | <1% | 111 | $718.33 | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 500 | $713.94 |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 13 | $685.61 |
| 83002 | <1% | 54 | $649.12 | |
| 82670 | <1% | 35 | $622.68 | |
| 94726 | <1% | 89 | $571.35 | |
| 82533 | <1% | 14 | $565.37 | |
| 87449 | <1% | 36 | $539.02 | |
| 82330 | <1% | 21 | $529.24 | |
| J1750 | Injection, iron dextran, 50 mg | <1% | 50 | $523.24 |
| 97161 | <1% | 12 | $516.31 | |
| 97163 | <1% | 21 | $474.80 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 719 | $401.33 |
| 73140 | <1% | 138 | $391.31 | |
| 96376 | <1% | 3,694 | $319.86 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 8,779 | $275.08 |
| 82010 | <1% | 47 | $258.62 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 15,844 | $233.35 |
| 86318 | <1% | 13 | $195.00 | |
| 80329 | <1% | 53 | $173.10 | |
| 88312 | <1% | 54 | $169.97 | |
| 80320 | <1% | 846 | $164.11 | |
| 83615 | <1% | 35 | $151.37 | |
| 83874 | <1% | 15 | $143.67 | |
| 77065 | Tomosynthesis, mammo | <1% | 18 | $142.26 |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 1,394 | $130.01 |
| 97165 | <1% | 15 | $125.32 | |
| 86705 | <1% | 21 | $123.54 | |
| 73560 | <1% | 85 | $103.96 | |
| 87075 | <1% | 37 | $97.32 | |
| 82952 | <1% | 34 | $95.54 | |
| 99152 | <1% | 728 | $90.78 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 29 | $90.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,786 | $79.77 |
| 85049 | <1% | 33 | $74.67 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 15,446 | $69.85 |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 15 | $58.80 |
| 88342 | <1% | 59 | $58.64 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 10,325 | $57.48 |
| 87324 | <1% | 19 | $56.13 | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 65 | $52.78 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 402 | $51.39 |
| 82248 | <1% | 13 | $48.61 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 5,137 | $48.25 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 5,600 | $47.72 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 10,928 | $36.35 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 4,458 | $36.24 |
| A9270 | Non-covered item or service | <1% | 16,985 | $35.35 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 1,552 | $32.66 |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 14 | $31.48 |
| 73090 | <1% | 19 | $26.92 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,304 | $22.83 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,896 | $17.65 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,691 | $14.45 |
| C1769 | Guide wire | <1% | 1,013 | $11.35 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,751 | $11.19 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 6,380 | $8.11 |
| 73080 | <1% | 44 | $8.09 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,747 | $7.97 |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 267 | $5.62 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 672 | $4.44 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,227 | $3.57 |
| G0475 | Hiv antigen/antibody, combination assay, screening | <1% | 17 | $2.96 |
| 99153 | Mod sedat endo service >5yrs | <1% | 211 | $1.93 |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | <1% | 184 | $1.20 |
| J3490 | Unclassified drugs | 0% | 261 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 2,662 | $0.00 |
| 74022 | 0% | 13 | $0.00 | |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 205 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 57 | $0.00 |
| 94644 | 0% | 26 | $0.00 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 82 | $0.00 |
| V2632 | Posterior chamber intraocular lens | 0% | 167 | $0.00 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 56 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 154 | $0.00 |
| 36416 | 0% | 44 | $0.00 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 13 | $0.00 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 0% | 14 | $0.00 |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 17 | $0.00 |
| J3360 | Injection, diazepam, up to 5 mg | 0% | 17 | $0.00 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 217 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 311 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 436 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 127 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 261 | $0.00 |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 930 | $0.00 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 740 | $0.00 |
| A4212 | Non-coring needle or stylet with or without catheter | 0% | 347 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 201 | $0.00 |
| 76000 | 0% | 37 | $0.00 | |
| J1756 | Injection, iron sucrose, 1 mg | 0% | 145 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 21 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 35 | $0.00 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 73 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 45 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 97 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 34 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 25 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMCCULLOUGH, MICHAEL (CFO)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.